For Q1 FY2026 ended March 31, 2026, ADMA Biologics reported revenue of $114.5 million, down 26.9% year-over-year. Net income was $45.3 million, up 68.5%, and diluted EPS was $0.19, up 72.7%. Operating income rose 67.1% to $58.3 million. The company had $138.2 million in cash, $390.3 million in equity, and $196.9 million in long-term debt.
•Revenue decreased 26.9% YoY to $114.5 million.
•Net income increased 68.5% YoY to $45.3 million.
•Diluted EPS grew 72.7% to $0.19.
•Operating income rose 67.1% to $58.3 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
ADMA Biologics, Inc., a biopharmaceutical company develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and globally.
Its operations are structured into ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI).
Its portfolio also includes ASCENIV, an IVIG product for the treatment of PI, and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin.
Additionally, it operates source plasma collection facilities. Distribution is handled through independent distributors, drug wholesalers, specialty pharmacies, and alternate site providers. Incorporated in 2004, ADMA Biologics is headquartered in Ramsey, New Jersey.
What does ADMA Biologics (ADMA) do and what are its main products?
ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its main products include BIVIGAM, an intravenous immune globulin (IVIG) product indicated for primary humoral immunodeficiency (PI); ASCENIV, another IVIG product for PI; and Nabi-HB, a human polyclonal antibody product for acute exposure to Hepatitis B. The company also has a pipeline of plasma-derived therapeutics, including products related to the treatment and prevention of S. pneumoniae infection. ADMA operates through two segments: ADMA BioManufacturing and Plasma Collection Centers, and it distributes its products via independent distributors, drug wholesalers, specialty pharmacies, and alternate site providers.
On which stock exchange is ADMA Biologics (ADMA) listed and what currency is used?
ADMA Biologics trades on the Nasdaq Global Market (NasdaqGM) under the ticker symbol ADMA. The company is headquartered in the United States, and its financials are reported in US Dollars (USD). As a US-based company listed on a major US exchange, investors can buy and sell ADMA shares in US dollars through any brokerage that offers access to Nasdaq-listed stocks.
What sector and industry does ADMA Biologics (ADMA) operate in?
ADMA Biologics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing plasma-derived biologics, which are therapeutic products derived from human blood plasma. These biologics are used to treat immune deficiencies and infectious diseases, placing ADMA at the intersection of biopharmaceutical development and specialty plasma collection. The company's operations encompass both manufacturing and plasma collection, making it a vertically integrated player in the biotechnology space.
Where is ADMA Biologics headquartered and what markets does it serve?
ADMA Biologics is headquartered in Ramsey, New Jersey, United States. The company was incorporated in 2004 and serves both the US and global markets. Its products are distributed through independent distributors, drug wholesalers, specialty pharmacies, and alternate site providers, ensuring broad reach to patients and healthcare providers. Additionally, ADMA operates source plasma collection facilities, which supply the raw material for its biologics, supporting its manufacturing operations domestically and internationally.
How does ADMA Biologics (ADMA) generate revenue and what are its key business segments?
ADMA Biologics generates revenue through the development, manufacture, and sale of plasma-derived biologics. Its operations are structured into two segments: ADMA BioManufacturing, which handles the production of its biologic products, and Plasma Collection Centers, which operate facilities that collect source plasma from donors. The company's approved products include BIVIGAM, ASCENIV, and Nabi-HB, which are sold to treat primary humoral immunodeficiency and Hepatitis B exposure. Revenue comes from sales to independent distributors, drug wholesalers, specialty pharmacies, and alternate site providers. ADMA also invests in a pipeline of plasma-derived therapeutics, such as treatments for S. pneumoniae infection, which may generate future revenue upon approval.